Literature DB >> 2574820

Different modes of action of 3-amino-1-hydroxy-2-pyrrolidone (HA-966) and 7-chlorokynurenic acid in the modulation of N-methyl-D-aspartate-sensitive glutamate receptors.

W Danysz1, E Fadda, J T Wroblewski, E Costa.   

Abstract

The N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors are known to be inhibited by 3-amino-1-hydroxy-2-pyrrolidone (HA-966) and 7-chlorokynurenic acid (Cl-KYN), which act at the glycine-regulated allosteric modulatory center. In this work we show that, in synaptic membranes prepared from rat brain, Cl-KYN and HA-966 inhibit the binding of [3H]glycine. Moreover, Cl-KYN can also completely inhibit the binding of [3H]glutamate to the primary transmitter recognition site for the NMDA receptor, whereas HA-966 only partially reduces this binding. Cl-KYN also abolishes the binding of the NMDA receptor antagonist [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP). In contrast, HA-966 increases [3H]CPP binding, affecting the affinity but not the maximal number of binding sites. This increase is inhibited by glycine and Cl-KYN. The binding of [3H] (+)-5-methyl-10,11-dihydro-5H-dibenzocyclohepten-5,10-imine maleate (MK-801), used as an index of NMDA receptor activation, is completely inhibited by Cl-KYN but only partially by HA-966. In addition, HA-966, but not Cl-KYN, increases the potency of CPP in inhibiting [3H]MK-801 binding. Our results demonstrate that Cl-KYN and HA-966 differ in their ability to modulate the NMDA receptor, perhaps acting at distinct but overlapping recognition sites. Furthermore, our results suggest that agonist and antagonist recognition sites of the NMDA receptor may be independently regulated by glycine and HA-966, which would result, respectively, in a positive and negative allosteric modulation of the NMDA receptor complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574820

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors.

Authors:  V Varga; Z Jenei; R Janáky; P Saransaari; S S Oja
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

Review 2.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

3.  Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor.

Authors:  G Henderson; J W Johnson; P Ascher
Journal:  J Physiol       Date:  1990-11       Impact factor: 5.182

4.  Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.

Authors:  K M Boje; S S Lakhman
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

5.  On central muscle relaxants, strychnine-insensitive glycine receptors and two old drugs: zoxazolamine and HA-966.

Authors:  B A McMillen; H L Williams; H Lehmann; P D Shepard
Journal:  J Neural Transm Gen Sect       Date:  1992

6.  Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.

Authors:  C B Carroll; V Holloway; J M Brotchie; I J Mitchell
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

Review 7.  Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.

Authors:  Trevor W Stone
Journal:  J Neurochem       Date:  2019-11-24       Impact factor: 5.372

Review 8.  Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.

Authors:  Tamás Biernacki; Dániel Sandi; Krisztina Bencsik; László Vécsei
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.